Modality
ERT
MOA
FGFRi
Target
KRASG12D
Pathway
Lipid Met
OCDMM
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
Oct 2018
→ Nov 2031
Phase 2Current
NCT05281409
2,960 pts·MM
2018-10→2031-11·Recruiting
2,960 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-014mo agoBTD· OCD
2031-11-085.6y awayPh3 Readout· MM
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Recruit…
Catalysts
BTD
2025-12-01 · 4mo ago
OCD
Ph3 Readout
2031-11-08 · 5.6y away
MM
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05281409 | Phase 2/3 | MM | Recruiting | 2960 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D |